CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and
tolerability of adding targeted agents to a standard chemotherapy. CP-868,596 is a
platelet-derived growth factor receptor inhibitor (PDGFR) and AG-13736 is a vascular
endothelial growth factor receptor inhibitor (VEGFR). This study will test the use of
docetaxel (the standard chemotherapy) with either CP-868,596 or the combination of CP-868,596
and AG-13736.